Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection

J Infect Dis. 2005 Aug 1;192(3):445-55. doi: 10.1086/431597. Epub 2005 Jun 29.

Abstract

We studied changes in 60 immunological parameters after the administration of highly active antiretroviral therapy (HAART) in 192 clinically stable antiretroviral drug-experienced HIV-1-infected children 4 months-17 years old. The studied immunological parameters included standard lymphocyte subsets and lymphocyte surface markers of maturation and activation. The most significant changes during the 48-week study period were seen for CD8(+), CD8(+)CD62L(+)CD45RA(+), CD8(+)CD38(+)HLA-DR(+), and CD4(+) T cell percentages (P < .0001 for all parameters). These changes suggest that significant decreases in the expression of activation markers and increases in the expression of naive markers in the CD8(+) T cell population may be related to better virologic control in these HIV-1-infected children, who had relatively stable immune function at the initiation of HAART. At week 44 of HAART, the major immunological parameters in these HIV-1-infected children moved from baseline values to about halfway to two-thirds of the way toward the values in healthy, uninfected children.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology*
  • Antigens, CD / blood
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • CD8-Positive T-Lymphocytes / immunology
  • Child
  • Flow Cytometry
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HLA-DR Antigens / blood
  • Humans
  • Lymphocyte Activation
  • Lymphocyte Count
  • T-Lymphocytes / immunology
  • Viral Load

Substances

  • Antigens, CD
  • HLA-DR Antigens